PRE-Treatment EXTent of tumour - number of contiguous liver sections FREE of tumour determines the group.
The Hepatoblastoma — PRETEXT Group is a oncology scoring tool used in paediatric practice. PRE-Treatment EXTent of tumour - number of contiguous liver sections FREE of tumour determines the group. It scores 1 criteria and interprets the total across 4 bands, so the number always arrives with the severity it implies rather than on its own. In PediAid each criterion is shown as a labelled option with the weight it carries, so the total can be checked rather than taken on trust.
1. They are Liver sections involved (of the four sections).
The total is interpreted as: 1 stage or more - PRETEXT I: pRETEXT I - upfront resection usually feasible; excellent prognosis; 2 stage or more - PRETEXT II: pRETEXT II - resectable at diagnosis or after neoadjuvant chemotherapy; 3 stage or more - PRETEXT III: pRETEXT III - neoadjuvant chemotherapy then re-evaluate (POST-TEXT); may need extended hepatectomy or transplant referral; 4 stage or more - PRETEXT IV: pRETEXT IV - all sections involved. Refer early for liver transplant evaluation alongside chemotherapy.
No. It is a structured way to record and communicate severity. A clinician concerned about a child should act on that concern regardless of the total.
Annotation factors modify risk: V (hepatic vein/IVC), P (portal vein), E (extrahepatic contiguous), F (multifocal), R (tumour rupture), C (caudate), N (nodes), M (distant metastases).
Yes. Score definitions are bundled with the PediAid app, so the score computes without a connection.